The largest database of trusted experimental protocols

RNA Sequence

RNA Sequence refers to the precise order of nucleotides within an RNA molecule.
Analyzing RNA sequences is crucial for understanding gene expression, cellular processes, and disease mechanisms.
PubCompare.ai's cutting-edge AI technology can optimize your RNA sequence research by helping you locate relevant protocols from literature, pre-prints, and patents.
Leveraging AI-driven comparisons, you can identify the best protocols and products to streamline your research effortlessly.
Discover how PubCompare.ai's powerful tools can elevate your RNA sequence studies and drive meaningful discoveries.
Streamlaine your RNA sequence research with PubCompare.ai today.

Most cited protocols related to «RNA Sequence»

SAMtools is a library and software package for parsing and manipulating alignments in the SAM/BAM format. It is able to convert from other alignment formats, sort and merge alignments, remove PCR duplicates, generate per-position information in the pileup format (Fig. 1c), call SNPs and short indel variants, and show alignments in a text-based viewer. For the example alignment of 112 Gbp Illumina GA data, SAMtools took about 10 h to convert from the MAQ format and 40 min to index with <30 MB memory. Conversion is slower mainly because compression with zlib is slower than decompression. External sorting writes temporary BAM files and would typically be twice as slow as conversion.
SAMtools has two separate implementations, one in C and the other in Java, with slightly different functionality.

Mandatory fields in the SAM format

No.NameDescription
1QNAMEQuery NAME of the read or the read pair
2FLAGBitwise FLAG (pairing, strand, mate strand, etc.)
3RNAMEReference sequence NAME
4POS1-Based leftmost POSition of clipped alignment
5MAPQMAPping Quality (Phred-scaled)
6CIGARExtended CIGAR string (operations: MIDNSHP)
7MRNMMate Reference NaMe (‘=’ if same as RNAME)
8MPOS1-Based leftmost Mate POSition
9ISIZEInferred Insert SIZE
10SEQQuery SEQuence on the same strand as the reference
11QUALQuery QUALity (ASCII-33=Phred base quality)
Publication 2009
Decompression DNA Library INDEL Mutation Memory Single Nucleotide Polymorphism
Geneious Basic is written in Java Swing to maximize interoperability among all commonly used operating systems. It is compiled under and requires Java 5 to run. The application provides core modules to enable the visualization, manipulation and transfer of DNA sequences (linear, circular and short oligos such as primers and probes), amino acid sequences, pair-wise and multiple alignments, phylogenetic trees, 3D structures, sequence chromatograms, contig assemblies, microsatellite electropherograms and statistical graphs.
The underlying software framework for Geneious Basic is modular and multi-tiered with a focus on handling bioinformatics data and tools (Fig. 1). It integrates a comprehensive plugin system which is grounded in the extensible Geneious API. The public API component allows plugin developers to leverage the functionality and user interface of the Geneious platform while concentrating on the development of processes and algorithms. The API download from the Geneious website provides a number of skeleton plugin examples to use as a basis for new plugins, allowing developers with a basic level of Java knowledge to develop fully functional plugins that greatly extend the functionality of Geneious Basic.

Modular overview of the Geneious Basic software stack. Top-most modules have dependencies on lower modules. The unshaded modules represent the publicly accessible modules for plugin development.

The public API allows developers to leverage online sequence search web services such as NCBI BLAST. Also using the public API, developers can implement plugins that exploit external binaries and even online computational resources, a growing trend in the field of Bioinformatics (Schatz et al., 2010 (link)).
Publication 2012
2',5'-oligoadenylate Amino Acid Sequence DNA Sequence Oligonucleotide Primers Short Tandem Repeat Skeleton
Reads were aligned using the TopHat2 aligner [65 (link)], and assigned to genes using the summarizeOverlaps function of the GenomicRanges package [60 (link)]. The sequence read archive fastq files of the Pickrell et al. [17 (link)] dataset (accession number [SRA:SRP001540]) were aligned to the Homo sapiens reference sequence GRCh37 downloaded in March 2013 from Illumina iGenomes. Reads were counted in the genes defined by the Ensembl GTF file, release 70, contained in the Illumina iGenome. The sequence read archive fastq files of the Bottomly et al. [16 (link)] dataset (accession number [SRA:SRP004777]) were aligned to the Mus musculus reference sequence NCBIM37 downloaded in March 2013 from Illumina iGenomes. Reads were counted in the genes defined by the Ensembl GTF file, release 66, contained in the Illumina iGenome.
Publication 2014
Genes Homo sapiens Mice, House
BWA supports paired-end mapping. It first finds the positions of all the good hits, sorts them according to the chromosomal coordinates and then does a linear scan through all the potential hits to pair the two ends. Calculating all the chromosomal coordinates requires to look up the suffix array frequently. This pairing process is time consuming as generating the full suffix array on the fly with the method described above is expensive. To accelerate pairing, we cache large intervals. This strategy halves the time spent on pairing.
In pairing, BWA processes 256K read pairs in a batch. In each batch, BWA loads the full BWA index into memory, generates the chromosomal coordinate for each occurrence, estimates the insert size distribution from read pairs with both ends mapped with mapping quality higher than 20, and then pairs them. After that, BWA clears the BWT index from the memory, loads the 2 bit encoded reference sequence and performs Smith–Waterman alignment for unmapped reads whose mates can be reliably aligned. Smith–Waterman alignment rescues some reads with excessive differences.
Publication 2009
Chromosomes Memory Radionuclide Imaging
The simulated protein alignments and the genuine COG alignments were described previously [2] (link). The 16S alignment with 237,882 distinct sequences was taken from GreenGenes [33] (link) (http://greengenes.lbl.gov). The 16S alignment with 15,011 distinct “families” is a non-redundant subset of these sequences ( identical). 16S alignments with 500 sequences are also non-redundant random subsets ( identical). Other large 16S alignments are from [11] (link).
For the 16S-like simulations with 78,132 distinct sequences, we used a maximum-likelihood tree inferred from a non-redundant aligned subset of the full set of 16S sequences ( % identity) by an earlier version of FastTree (1.9) with the Jukes-Cantor model (no CAT). To ensure that the simulated trees were resolvable, which facilitates comparison of methods (but inflates the accuracy of all methods), branch lengths of less than 0.001 were replaced with values of 0.001, which corresponds to roughly one substitution across the internal branch, as the 16S alignment has 1,287 positions. Evolutionary rates for each site were randomly selected from 16 rate categories according to a gamma distribution with a coefficient of variation of 0.7. Given the tree and the rates, sequences were simulated with Rose [34] (link) under the HKY model and no transition bias. To allow Rose to handle branch lengths of less than 1%, we set “MeanSubstitution = 0.00134” and multiplied the branch lengths by 1,000.
Publication 2010
Biological Evolution Cantor Gamma Rays Proteins Sequence Alignment Trees

Most recents protocols related to «RNA Sequence»

Example 17

To further validate the activity of the DMPK siRNAs, many of the sequences that showed the best activity in the initial screen were selected for a follow-up evaluation in dose response format. Once again, two human cell lines were used to assess the in vitro activity of the DMPK siRNAs: first, SJCRH30 human rhabdomyosarcoma cell line; and second, Myotonic Dystrophy Type 1 (DM1) patient-derived immortalized human skeletal myoblasts. The selected siRNAs were transfected in a 10-fold dose response at 100, 10, 1, 0.1, 0.01, 0,001, and 0.0001 nM final concentrations or in a 9-fold dose response at 50, 5.55556, 0.617284, 0.068587, 0.007621, 0.000847, and 0.000094 nM final concentrations. The siRNAs were formulated with transfection reagent Lipofectamine RNAiMAX (Life Technologies) according to the manufacturer's “forward transfection” instructions. Cells were plated 24 h prior to transfection in triplicate on 96-well tissue culture plates, with 8500 cells per well for SJCRH30 and 4000 cells per well for DM1 myoblasts. At 48 h (SJCRH30) or 72 h (DM1 myoblasts) post-transfection cells were washed with PBS and harvested with TRIzol® reagent (Life Technologies). RNA was isolated using the Direct-zol-96 RNA Kit (Zymo Research) according to the manufacturer's instructions. 10 μl of RNA was reverse transcribed to cDNA using the High Capacity cDNA Reverse Transcription Kit (Applied Biosystems) according to the manufacturer's instructions. cDNA samples were evaluated by qPCR with DMPK-specific and PPIB-specific TaqMan human gene expression probes (Thermo Fisher) using TaqMan® Fast Advanced Master Mix (Applied Biosystems). DMPK values were normalized within each sample to PPIB gene expression. The quantification of DMPK downregulation was performed using the standard 2−ΔΔCt a method. All experiments were performed in triplicate, with Tables 16A-B, 17A-B, and 18A-B presenting the mean values of the triplicates as well as the calculated IC50 values determined from fitting curves to the dose-response data by non-linear regression.

TABLE 16A
sense strandSEQantisense strandSEQ
sequence (5′-3′)IDsequence (5′-3′)ID
ID #1Passenger Strand (PS)NO:Guide Strand (GS)NO:
535GGGCGAGGUGUCGUGCUUA9349UAAGCACGACACCUCGCCC12053
584GACCGGCGGUGGAUCACGA9398UCGUGAUCCACCGCCGGUC12102
716AUGGCGCGCUUCUACCUGA9530UCAGGUAGAAGCGCGCCAU12234
1028CAGACGCCCUUCUACGCGA9842UCGCGUAGAAGGGCGUCUG12546
1276UUUCGAAGGUGCCACCGAA10090UUCGGUGGCACCUUCGAAA12794
1825UGCUCCUGUUCGCCGUUGA10639UCAACGGCGAACAGGAGCA13343
1945CCCUAGAACUGUCUUCGAA10759UUCGAAGACAGUUCUAGGG13463
2529CUUCGGCGGUUUGGAUAUA11343UAUAUCCAAACCGCCGAAG14047
2558GUCCUCCGACUCGCUGACA11372UGUCAGCGAGUCGGAGGAC14076
2628CCGACAUUCCUCGGUAUUA11442UAAUACCGAGGAAUGUCGG14146
2636CCUCGGUAUUUAUUGUCUA11450UAGACAAUAAAUACCGAGG14154
119mer position in NM_001288766.1

TABLE 16B
IC50
ID #1qPCR2qPCR3qPCR4qPCR5qPCR6qPCR7qPCR8(nM)
535111.9105.4106.382.436.729.535.70.165
58490.590.284.767.838.025.828.30.190
71688.985.281.962.032.619.320.30.181
102888.581.883.061.332.727.331.50.127
127687.085.084.066.140.534.036.40.150
182585.185.983.769.136.225.225.00.259
194585.081.774.444.922.917.717.20.070
252983.381.875.350.624.617.517.70.103
255884.381.174.345.423.413.311.80.088
262885.384.079.559.830.323.525.10.140
263686.386.974.344.019.812.413.00.070
2SJCRH30; 0.0001 nM; % DMPK mRNA
3SJCRH30; 0.001 nM; % DMPK mRNA
4SJCRH30; 0.01 nM; % DMPK mRNA
5SJCRH30; 0.1 nM; % DMPK mRNA
6SJCRH30; 1 nM; % DMPK mRNA
7SJCRH30; 10 nM; % DMPK mRNA
8SJCRH30; 100 nM; % DMPK mRNA

TABLE 17A
sense strandSEQantisense strandSEQ
sequence (5′-3′)IDsequence (5′-3′)ID
ID #1Passenger Strand (PS)NO:Guide Strand (GS)NO:
2600CAAUCCACGUUUUGGAUGA11414UCAUCCAAAACGUGGAUUG14118
2636CCUCGGUAUUUAUUGUCUA11450UAGACAAUAAAUACCGAGG14154
2675CCCCGACCCUCGCGAAUAA11489UUAUUCGCGAGGGUCGGGG14193
2676CCCGACCCUCGCGAAUAAA11490UUUAUUCGCGAGGGUCGGG14194
2679GACCCUCGCGAAUAAAAGA11493UCUUUUAUUCGCGAGGGUC14197
2680ACCCUCGCGAAUAAAAGGA11494UCCUUUUAUUCGCGAGGGU14198
2681CCCUCGCGAAUAAAAGGCA11495UGCCUUUUAUUCGCGAGGG14199
2682CCUCGCGAAUAAAAGGCCA11496UGGCCUUUUAUUCGCGAGG14200
119mer position in NM_001288766.1

TABLE 17B
IC50
ID #1qPCR2qPCR3qPCR4qPCR5qPCR6qPCR7(nM)
2600107.5107.6108.1106.3103.172.731.31
263681.181.174.047.225.711.50.073
267588.188.384.364.638.120.70.151
267688.978.984.472.744.935.60.204
267984.087.382.753.331.413.50.091
268087.485.385.168.544.539.60.110
268187.085.477.649.626.516.00.061
268282.483.977.150.827.331.10.047
2SJCRH30; 0.000094 nM; % DMPK mRNA
3SJCRH30; 0.000847 nM; % DMPK mRNA
4SJCRH30; 0.007621 nM; % DMPK mRNA
5SJCRH30; 0.068587 nM; % DMPK mRNA
6SJCRH30; 0.617284 nM; % DMPK mRNA
7SJCRH30; 5.55556 nM; % DMPK mRNA

TABLE 18A
sense strandSEQantisense strandSEQ
sequence (5′-3′)IDsequence (5′-3′)ID
ID #1Passenger Strand (PS)NO:Guide Strand (GS)NO:
584GACCGGCGGUGGAUCACGA9398UCGUGAUCCACCGCCGGUC12102
716AUGGCGCGCUUCUACCUGA9530UCAGGUAGAAGCGCGCCAU12234
1265UUUACACCGGAUUUCGAAA10079UUUCGAAAUCCGGUGUAAA12783
1297AUGCAACUUCGACUUGGUA10111UACCAAGUCGAAGUUGCAU12815
1945CCCUAGAACUGUCUUCGAA10759UUCGAAGACAGUUCUAGGG13463
1960CGACUCCGGGGCCCCGUUA10774UAACGGGGCCCCGGAGUCG13478
2529CUUCGGCGGUUUGGAUAUA11343UAUAUCCAAACCGCCGAAG14047
2530UUCGGCGGUUUGGAUAUUA11344UAAUAUCCAAACCGCCGAA14048
2531UCGGCGGUUUGGAUAUUUA11345UAAAUAUCCAAACCGCCGA14049
2554CCUCGUCCUCCGACUCGCA11368UGCGAGUCGGAGGACGAGG14072
2628CCGACAUUCCUCGGUAUUA11442UAAUACCGAGGAAUGUCGG14146
2629CGACAUUCCUCGGUAUUUA11443UAAAUACCGAGGAAUGUCG14147
2681CCCUCGCGAAUAAAAGGCA11495UGCCUUUUAUUCGCGAGGG14199
119mer position in NM_001288766.1

TABLE 18B
IC50
ID #1qPCR2qPCR3qPCR4qPCR5qPCR6qPCR7(nM)
58490.877.097.771.945.029.70.228
71696.582.577.064.643.333.90.080
126568.580.968.057.137.525.70.146
129771.467.269.453.540.525.40.171
194571.862.341.729.822.415.30.006
196063.065.462.145.831.128.30.068
252963.558.749.231.122.921.90.017
253069.366.753.143.238.824.50.016
253169.972.457.340.235.425.60.018
255468.270.151.243.032.117.30.043
262869.767.962.538.431.617.10.042
262972.165.669.042.134.413.70.078
268182.491.587.655.529.319.60.084
2DM1 myoblasts; 0.000094 nM; % DMPK mRNA
3DM1 myoblasts; 0.000847 nM; % DMPK mRNA
4DM1 myoblasts; 0.007621 nM; % DMPK mRNA
5DM1 myoblasts; 0.068587 nM; % DMPK mRNA
6DM1 myoblasts; 0.617284 nM; % DMPK mRNA
7DM1 myoblasts; 5.55556 nM; % DMPK mRNA

Patent 2024
Cell Lines Cells DNA, Complementary Down-Regulation Gene Expression Homo sapiens Lipofectamine Myoblasts Myoblasts, Skeletal Myotonic Dystrophy NM-107 Patients PPIB protein, human Reverse Transcription Rhabdomyosarcoma RNA, Messenger RNA, Small Interfering Tissues Transfection trizol

Example 3

We tested the ability of mouse embryonic stem cells to tolerate s4U metabolic RNA-labeling after 12 h or 24 h at varying s4U concentrations (FIG. 6A). As reported previously, high concentrations of s4U compromised cell viability with an EC50 of 3.1 mM or 380 μM after 12 h or 24 h labeling, respectively (FIG. 6A). Hence, we employed labeling conditions of 100 μM s4U, which did not severely affect cell viability. Under these conditions, we detected a steady increase in s4U-incorporation in total RNA preparation 3 h, 6 h, 12 h, and 24 h post labeling, as well as a steady decrease 3 h, 6 h, 12 h, and 24 h after uridine chase (FIG. 6B). As expected, the incorporation follows a single exponential kinetics, with a maximum average incorporation of 1.78% s4U, corresponding to one s4U incorporation in every 56 uridines in total RNA (FIG. 6C). These experiments establish s4U-labeling conditions in mES cells, which can be employed to measure RNA biogenesis and turnover rates under unperturbed conditions.

To test the ability of the method to uncover s4U incorporation events in high throughput sequencing datasets we generated mRNA 3′ end libraries (employing Lexogen's QuantSeq, 3′ mRNA-sequencing library preparation kit) using total RNA prepared from cultured cells following s4U-metabolic RNA labeling for 24 h (FIG. 7) (Moll et al., supra). Quant-seq 3′ mRNA-Seq Library Prep Kit generates Illumina-compatible libraries of the sequences close to the 3′end of the polyadenylated RNA, as exemplified for the gene Trim28 (FIG. 8A). In contrast to other mRNA-sequencing protocols, only one fragment per transcript is generated and therefore no normalization of reads to gene length is needed. This results in accurate gene expression values with high strand-specificity.

Furthermore, sequencing-ready libraries can be generated within only 4.5 h, with ˜2 h hands-on time. When combined with the invention, Quant-seq facilitates the accurate determination of mutation rates across transcript-specific regions because libraries exhibit a low degree of sequence-heterogeneity. Indeed, upon generating libraries of U-modified RNA through the Quant-seq protocol from total RNA of mES cells 24 h after s4U metabolic labeling we observed a strong accumulation of T>C conversions when compared to libraries prepared from total RNA of unlabeled mES cells (FIG. 8B). In order to confirm this observation transcriptome-wide, we aligned reads to annotated 3′ UTRs and inspected the occurrence of any given mutation per UTR (FIG. 9). In the absence of s4U metabolic labeling, we observed a median mutation rate of 0.1% or less for any given mutation, a rate that is consistent with Illumina-reported sequencing error rates. After 24 h of s4U metabolic labeling, we observed a statistically significant (p<10−4, Mann-Whitney test), 25-fold increase in T>C mutation rates, while all other mutations rates remained below expected sequencing error rates (FIG. 9). More specifically, we measured a median s4U-incorporation of 2.56% after 24 h labeling, corresponding to one s4U incorporation in every 39 uridines. (Note, that median incorporation frequency for mRNA are higher than estimated by HPLC in total RNA [FIG. 6C], most certainly because stable non-coding RNA species, such as rRNA, are strongly overrepresented in total RNA.) These analyses confirm that the new method uncovers s4U-incorporation events in mRNA following s4U-metabolic RNA labeling in cultured cells.

We expect the same incorporation results of other modified nucleotides, such as s6G or 5-ethynyluridine, as reported previously (Eidinoff et al., Science. 129, 1550-1551 (1959); Jao et al. PNAS 105, 15779-15784 (2008); Melvin et al. Eur. J. Biochem. 92, 373-379 (1978); Woodford et al. Anal. Biochem. 171, 166-172 (1988)).

Patent 2024
Anabolism Anus Cells Cell Survival Cultured Cells DNA Library Gene Expression Genes Genetic Heterogeneity High-Performance Liquid Chromatographies Kinetics Mouse Embryonic Stem Cells Mutation Nucleotides Peptide Nucleic Acids Preparation H Ribosomal RNA RNA, Messenger RNA, Polyadenylated RNA, Untranslated Transcriptome TRIM28 protein, human Uridine Whole Transcriptome Sequencing

Example 2

Serum stability assay of GalNAc-siRNA conjugates containing two PS (STS12009L4), one PS (STS12009V21L4), two PS2 (STS12009V16L4) and one PS2 (STS12009V15L4) at terminal positions. GalNAc was conjugated to the 5′-end of the second strand and is internally stabilized by four PS. Phosphorothioates and phosphorodithioates, respectively were placed at the 5′-end of the first strand, 3′-end of the first strand and 3′-end of the second strand. 5 μM GalNAc-siRNA conjugates were incubated with 50% FBS for 3 d at 37° C. RNA was extracted and analysed on 20% TBE polyacrylamide gels and results are shown in FIG. 1. “UT” indicates untreated samples, “FBS” indicates FBS treatment. “Control” indicates a less stabilized GalNAc-siRNA conjugate of different sequence. The sequences are set out in Table 3.

TABLE 3
GalNAc-siRNA conjugates containing two PS, one PS, two PS2 and one PS2 at
all non-conjugated ends.
sequence and chemistry
duplex ID(top: first strand, bottom: second strand, both 5′-3′)
STS12009L4mA(ps)fA(ps)mCfCmAfGmAfAmGfAmAfGmCfAmGfGmU(ps)fG(ps)mA
[ST23(ps)]3 ST41(ps)fUmCfAmCfCmUfGmCfUmUfCmUfUmCfUmGfG(ps)mU(ps)fU
STS12009V21L4mA(ps)fAmCfCmAfGmAfAmGfAmAfGmCfAmGfGmUfG(ps)mA
[ST23(ps)]3 ST41(ps)fUmCfAmCfCmUfGmCfUmUfCmUfUmCfUmGfGmU(ps)fU
STS12009V16L4mA(ps2)fA(ps2)mCfCmAfGmAfAmGfAmAfGmCfAmGfGmU(ps2)fG(ps2)mA
[ST23(ps)]3 ST41(ps)fUmCfAmCfCmUfGmCfUmUfCmUfUmCfUmGfG(ps2)mU(ps2)fU
STS12009V15L4mA(ps2)fAmCfCmAfGmAfAmGfAmAfGmCfAmGfGmUfG(ps2)mA
[ST23(ps)]3 ST41(ps)fUmCfAmCfCmUfGmCfUmUfCmUfUmCfUmGfGmU(ps2)fU
mA, mU, mC, mG-2′-OMe RNA
fA, fU, fC, fG - 2′-F RNA
(ps)- phosphorothioate
(ps2)- phosphorodithioate

Patent 2024
Biological Assay Cardiac Arrest Gene Expression Nucleic Acids phosphorodithioic acid polyacrylamide gels RNA, Small Interfering Serum

Example 4

FIGS. 5A-B show an exemplary nucleic acid library method to reverse the orientation of an analyte sequence in a member of a nucleic acid library. FIG. 5A shows an exemplary member of a nucleic acid library including, in a 5′ to 3′ direction, a ligation sequence, a barcode (e.g., a spatial barcode or a cell barcode), unique molecular identifier, a reverse complement of a first adaptor, an amplification domain, a capture domain, a sequence complementary to an analyte, and a second adapter.

The ends of the double-stranded nucleic acid can be ligated together via a ligation reaction where the ligation sequence splints the ligation to generate a circularized double-stranded nucleic acid also shown in FIG. 5A.

The circularized double-stranded nucleic acid can be amplified to generate a linearized double-stranded nucleic acid product, where the orientation of the analyte is reversed such that the 5′ sequence (e.g., 5′ UTR) is brought in closer proximity to the barcode (e.g., a spatial barcode or a cell barcode) (FIG. 5B). The first primer includes a sequence substantially complementary to the reverse complement of the first adaptor and a functional domain. The functional domain can be a sequencer specific flow cell attachment sequence (e.g., P5). The second primer includes a sequence substantially complementary to the amplification domain.

The resulting double-stranded member of the nucleic acid library including a reversed analyte sequence (e.g., the 5′ end of the analyte sequence is brought in closer proximity to the barcode) can undergo standard library preparation methods, such as library preparation methods used in single-cell or spatial analyses. For example, the double-stranded member of the nucleic acid library lacking all, or a portion of, the sequence encoding the constant region of the analyte can be fragmented, followed by end repair, A-tailing, adaptor ligation, and/or amplification (e.g., PCR) (FIG. 5C). The fragments can then be sequenced using, for example, paired-end sequencing using TruSeq Read 1 and TruSeq Read 2 as sequencing primer sites, or any other sequencing method described herein.

As a result of the methods described in this Example, sequences from the 5′ end of an analyte will be included in sequencing libraries (e.g., paired end sequencing libraries). Any type of analyte sequence in a nucleic acid library can be prepared by the methods described in this Example (e.g., reversed).

Patent 2024
5' Untranslated Regions Cell-Matrix Junction Cells DNA Library Ligation Nucleic Acids Oligonucleotide Primers Splints Standard Preparations

Example 3

    • (1) Prepared a nickel oxalate dihydrate NiC2O4·2H2O solution A with a concentration of 3 mol/L. Specifically, NiC2O4·2H2O was added to 50 mL of deionized water and stirred for 30 minutes to form a uniformly mixed solution A;
    • (2) Put the solution A into a polytetrafluoroethylene lined autoclave, the volume filling ratio was maintained at 50%;
    • (3) Took a 50 mL beaker, and completely immersed the foamed copper with a length of 7 cm and a width of 1 cm into acetone, 3 mol/L HCl solution, deionized water, and absolute ethanol in sequence, and carried out ultrasonic treatment separately for 30 minutes. Put the processed foamed copper into a polytetrafluoroethylene reactor containing the solution A; put the sealed reactor into a homogeneous hydrothermal reactor, the temperature parameter was set to 180° C., and the reaction time was 18 hours;
    • (4) After the reaction was completed and cooled to room temperature, the foamed copper after the reaction was taken out and washed with absolute ethanol and deionized water for 3 times;
    • (5) Prepared a solution B of tungsten hexachloride WCl6 with a concentration of 4 mol/L. Specifically, added WCl6 to 60 mL of deionized water and stirred it for 30 minutes to form a uniformly mixed solution B;
    • (6) Immersed the NiOOH/Cu2O-grown foamed copper in a polytetrafluoroethylene lined autoclave containing the solution B and sealed it, and the volume filling ratio was maintained at 60%. Put the sealed autoclave into a homogeneous hydrothermal reactor, the temperature parameter was set to 140° C., and the reaction time was 30 hours;
    • (7) After the reaction was completed, cooled to room temperature, took out the foamed copper after the reaction, and washed with absolute ethanol and deionized water 3 times. Put it into a 60° C. vacuum oven or a freeze-drying oven to dry for 6 hours to obtain a NiOOH/Cu2O/WO3/CF self-supporting electrocatalytic material. The total loading of NiOOH/Cu2O/WO3 was 3 mg/cm2. The molar ratio of WO3, Cu2O, and NiOOH was 1:0.6:0.05.

Patent 2024
Acetone Copper Ethanol Molar Nickel Oxalates Polytetrafluoroethylene Tungsten Ultrasonics Vacuum

Top products related to «RNA Sequence»

Sourced in United States, China, Japan, Germany, United Kingdom, Canada, France, Italy, Australia, Spain, Switzerland, Netherlands, Belgium, Lithuania, Denmark, Singapore, New Zealand, India, Brazil, Argentina, Sweden, Norway, Austria, Poland, Finland, Israel, Hong Kong, Cameroon, Sao Tome and Principe, Macao, Taiwan, Province of China, Thailand
TRIzol reagent is a monophasic solution of phenol, guanidine isothiocyanate, and other proprietary components designed for the isolation of total RNA, DNA, and proteins from a variety of biological samples. The reagent maintains the integrity of the RNA while disrupting cells and dissolving cell components.
Sourced in United States, China, Germany, United Kingdom, Canada, Japan, France, Italy, Switzerland, Australia, Spain, Belgium, Denmark, Singapore, India, Netherlands, Sweden, New Zealand, Portugal, Poland, Israel, Lithuania, Hong Kong, Argentina, Ireland, Austria, Czechia, Cameroon, Taiwan, Province of China, Morocco
Lipofectamine 2000 is a cationic lipid-based transfection reagent designed for efficient and reliable delivery of nucleic acids, such as plasmid DNA and small interfering RNA (siRNA), into a wide range of eukaryotic cell types. It facilitates the formation of complexes between the nucleic acid and the lipid components, which can then be introduced into cells to enable gene expression or gene silencing studies.
Sourced in United States, Germany, China, Japan, United Kingdom, Canada, France, Italy, Australia, Spain, Switzerland, Belgium, Denmark, Netherlands, India, Ireland, Lithuania, Singapore, Sweden, Norway, Austria, Brazil, Argentina, Hungary, Sao Tome and Principe, New Zealand, Hong Kong, Cameroon, Philippines
TRIzol is a monophasic solution of phenol and guanidine isothiocyanate that is used for the isolation of total RNA from various biological samples. It is a reagent designed to facilitate the disruption of cells and the subsequent isolation of RNA.
Sourced in Germany, United States, United Kingdom, Netherlands, Spain, Japan, Canada, France, China, Australia, Italy, Switzerland, Sweden, Belgium, Denmark, India, Jamaica, Singapore, Poland, Lithuania, Brazil, New Zealand, Austria, Hong Kong, Portugal, Romania, Cameroon, Norway
The RNeasy Mini Kit is a laboratory equipment designed for the purification of total RNA from a variety of sample types, including animal cells, tissues, and other biological materials. The kit utilizes a silica-based membrane technology to selectively bind and isolate RNA molecules, allowing for efficient extraction and recovery of high-quality RNA.
Sourced in United States, China, Germany, Japan, United Kingdom, France, Canada, Italy, Australia, Switzerland, Denmark, Spain, Singapore, Belgium, Lithuania, Israel, Sweden, Austria, Moldova, Republic of, Greece, Azerbaijan, Finland
Lipofectamine 3000 is a transfection reagent used for the efficient delivery of nucleic acids, such as plasmid DNA, siRNA, and mRNA, into a variety of mammalian cell types. It facilitates the entry of these molecules into the cells, enabling their expression or silencing.
Sourced in Japan, China, United States, France, Germany, Switzerland, Canada, Sweden, Italy, Puerto Rico, Singapore
The PrimeScript RT reagent kit is a reverse transcription kit designed for the synthesis of first-strand cDNA from RNA templates. The kit includes RNase-free reagents and enzymes necessary for the reverse transcription process.
Sourced in United States, China, Germany, United Kingdom, Hong Kong, Canada, Switzerland, Australia, France, Japan, Italy, Sweden, Denmark, Cameroon, Spain, India, Netherlands, Belgium, Norway, Singapore, Brazil
The HiSeq 2000 is a high-throughput DNA sequencing system designed by Illumina. It utilizes sequencing-by-synthesis technology to generate large volumes of sequence data. The HiSeq 2000 is capable of producing up to 600 gigabases of sequence data per run.
Sourced in United States, China, Germany, United Kingdom, Canada, Switzerland, Sweden, Japan, Australia, France, India, Hong Kong, Spain, Cameroon, Austria, Denmark, Italy, Singapore, Brazil, Finland, Norway, Netherlands, Belgium, Israel
The HiSeq 2500 is a high-throughput DNA sequencing system designed for a wide range of applications, including whole-genome sequencing, targeted sequencing, and transcriptome analysis. The system utilizes Illumina's proprietary sequencing-by-synthesis technology to generate high-quality sequencing data with speed and accuracy.
Sourced in United States, Germany, United Kingdom, Japan, Lithuania, France, Italy, China, Spain, Canada, Switzerland, Poland, Australia, Belgium, Denmark, Sweden, Hungary, Austria, Ireland, Netherlands, Brazil, Macao, Israel, Singapore, Egypt, Morocco, Palestine, State of, Slovakia
The High-Capacity cDNA Reverse Transcription Kit is a laboratory tool used to convert RNA into complementary DNA (cDNA) molecules. It provides a reliable and efficient method for performing reverse transcription, a fundamental step in various molecular biology applications.
Sourced in United States, China, United Kingdom, Germany, Japan, France, Canada, Switzerland, Denmark, Belgium, Italy, Australia, Singapore, Spain, Colombia, Sweden, Netherlands, New Zealand, Poland, Pakistan, Lithuania
Lipofectamine RNAiMAX is a transfection reagent designed for efficient delivery of small interfering RNA (siRNA) and short hairpin RNA (shRNA) into a wide range of cell types. It is a cationic lipid-based formulation that facilitates the uptake of these nucleic acids into the target cells.

More about "RNA Sequence"

Analyzing the precise order of nucleotides within ribonucleic acid (RNA) molecules is crucial for understanding gene expression, cellular processes, and disease mechanisms.
RNA sequencing is a powerful technique that enables researchers to explore transcriptome-wide patterns and uncover insights into various biological systems.
To streamline your RNA sequence research, consider leveraging cutting-edge AI technology like PubCompare.ai.
This innovative platform can help you locate relevant protocols from literature, pre-prints, and patents, allowing you to identify the best methods and products to optimize your workflow.
PubCompare.ai's AI-driven comparisons can help you navigate the vast landscape of RNA sequence research, guiding you towards the most effective protocols and tools.
Whether you're working with TRIzol reagent, Lipofectamine 2000, RNeasy Mini Kit, or other widely used RNA extraction and reverse transcription kits, PubCompare.ai can assist you in streamlining your processes and driving meaningful discoveries.
By leveraging the power of AI, you can effortlessly compare and evaluate different RNA sequencing approaches, including methods that utilize the HiSeq 2000, HiSeq 2500, or High-Capacity cDNA Reverse Transcription Kit.
Lipofectamine RNAiMAX can also be an invaluable tool for delivering small interfering RNA (siRNA) or other nucleic acids into cells, enabling further exploration of RNA-related processes.
Embark on your RNA sequence research journey with confidence, utilizing the cutting-edge technologies and AI-powered insights offered by PubCompare.ai.
Streamline your workflow, optimize your protocols, and unlock new possibilities in the realm of gene expression, cellular function, and disease understanding.